Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PEPD | P12955 | 1/20 | 0.36 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 4/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | GRM8 | O00222 | 1/20 | 0.32 |
| ▸ | GRM6 | O15303 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL44685 | 0.86 | SUCNR1 (0.39) | MEN1KMT2ABLMPEPDSUCNR1 | |
| Hydrochloric Acid SCHEMBL628216 | 0.84 | SUCNR1 (0.38) | MEN1KMT2ABLMPEPDSUCNR1 | |
| Hydrochloric Acid SCHEMBL1189461 | 0.84 | SUCNR1 (0.38) | MEN1KMT2ABLMPEPDSUCNR1 | |
| SCHEMBL20599827 | 0.77 | BTK (0.38) | ALDH1A1LMNA | |
| SCHEMBL27952996 | 0.76 | GAA (0.35) | KMT2ASUCNR1ALDH1A1LMNATDP1 | |
| SCHEMBL11298204 | 0.75 | SUCNR1 (0.43) | SUCNR1ALDH1A1 | |
| SCHEMBL7029407 | 0.75 | SUCNR1 (0.36) | SUCNR1LMNA | |
| SCHEMBL3650964 | 0.72 | ALDH1A1 (0.34) | SUCNR1ALDH1A1LMNA | |
| SCHEMBL28611363 | 0.72 | SUCNR1 (0.50) | MEN1KMT2ABLMSUCNR1ALDH1A1 | |
| SCHEMBL28269914 | 0.71 | GABRR1 (0.36) | MEN1KMT2APEPDALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120059154-A | In C4Method for producing polybutylene succinate polyester by taking unsaturated binary oxygen-containing compound as raw material | 上海师范大学 | 2025-05-30 | — | — | CN | claimed |
| US-7344704-B2 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of intravascular thrombi | SCHERING AG (DE) | 2008-03-18 | — | — | US | claimed |
| EP-1088558-B1 | Galenic formulations comprising paramagnetic and diamagnetic compounds | BAYER SCHERING PHARMA AG (DE) | 2007-06-27 | — | — | EP | claimed |
| EP-1519756-B1 | USE OF METAL COMPLEXES CONTAINING PERFLUOROALKYL AS CONTRAST AGENTS IN MAGNETIC RESONANCE IMAGING FOR REPRESENTING INTRAVASCULAR THROMBI | BAYER SCHERING PHARMA AG (DE) | 2007-05-02 | — | — | EP | claimed |
| US-6818203-B2 | COMPLEXES HAVE CRITICAL MICELLE FORMATION CONCENTRATION, HYDRODYNAMIC MICELLE DIAMETER, AND PROTON RELAXIVITY IN PLASMA CONTRAST MEDIA IN MR IMAGING | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-11-16 | — | — | US | claimed |
| US-20040131546-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of intravascular thrombi | SCHERING AG (DE) | 2004-07-08 | — | — | US | claimed |
| US-20030095924-A1 | Galenical formulations | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-05-22 | — | — | US | claimed |
| US-20030072713-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2003-04-17 | — | — | US | claimed |
| CN-120059154-A | In C4Method for producing polybutylene succinate polyester by taking unsaturated binary oxygen-containing compound as raw material | 上海师范大学 | 2025-05-30 | — | — | CN | disclosed |
| CN-119569706-A | Therapeutic compounds | 希四克斯探索有限公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-112996785-B | Therapeutic compounds | 希四克斯探索有限公司 | 2024-12-06 | — | — | CN | disclosed |
| CN-112978709-A | Carbon quantum dot precursor composition, carbon quantum dot and preparation method thereof | 中国科学院大连化学物理研究所 | 2021-06-18 | — | — | CN | disclosed |
| EP-2125054-A2 | PARTIALLY BIOABSORBABLE IMPLANT | CINVENTION AG (DE) | 2009-12-02 | — | — | EP | disclosed |
| EP-2120807-A2 | DEGRADABLE RESERVOIR IMPLANTS | CINVENTION AG (DE) | 2009-11-25 | — | — | EP | disclosed |
| US-20060093554-A1 | Galenical formulations | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-05-04 | — | — | US | disclosed |
| US-20050074409-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-04-07 | — | — | US | disclosed |
| US-6818203-B2 | COMPLEXES HAVE CRITICAL MICELLE FORMATION CONCENTRATION, HYDRODYNAMIC MICELLE DIAMETER, AND PROTON RELAXIVITY IN PLASMA CONTRAST MEDIA IN MR IMAGING | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-11-16 | — | — | US | disclosed |
| US-20030095924-A1 | Galenical formulations | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-05-22 | — | — | US | disclosed |
| US-20030072713-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2003-04-17 | — | — | US | disclosed |
| US-6447749-B1 | Perfluoro-alkyl containing dye molecules and galencial formulations | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030072713-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses | FABP3, PRF1, PTDSS1 | MEN1 398/4885KMT2A 4662/4885BLM 4081/4885 |
| US-20050074409-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses | FABP3, PRF1, MALT1 | MEN1 242/4885KMT2A 4638/4885BLM 3807/4885 |
| US-20060093554-A1 | Galenical formulations | GALC, GALR2, GALR1 | MEN1 466/4885KMT2A 2945/4885BLM 1860/4885 |
| US-20040131546-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of intravascular thrombi | PF4, FGB, F2 | MEN1 180/4885KMT2A 2972/4885BLM 2570/4885 |
| US-20030095924-A1 | Galenical formulations | GALR1, GALR2, LGALS1 | MEN1 1210/4885KMT2A 3664/4885BLM 2260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.